US EditionWuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody
WuXi Biologics will support Sinorda Biomedicine in advancing SND006's development and IND filings targeting inflammatory bowel disease and autoimmune disorders.
- On Jan. 28, 2026 in Shanghai, WuXi Biologics and Sinorda Biomedicine announced a strategic collaboration to develop and manufacture SND006 for IBD and autoimmune diseases.
- Sinorda Biomedicine, established in 2010, is a commercialization-stage biotech with early-stage bispecific antibody pipelines targeting IBD.
- With over 12,000 skilled employees, WuXi Biologics supports 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.
- Sinorda plans to submit IND applications in 2026 to the NMPA and FDA, leveraging WuXi to advance preclinical pharmacology and produce clinical supply, accelerating filings.
- The collaboration could expand to multiple integrated projects from discovery to manufacturing, with WuXi aiming to make biologics more accessible for patients with IBD and other autoimmune diseases.
29 Articles
29 Articles
Watauga Democrat
WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody
SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific antibody, for…
WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody - WuXi Biologics (Cayman) (OTC:WXXWY)
SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific antibody, for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune diseases. Under the agreement, Sinorda Biomedicine will …
China again: Boehringer turns to Shanghai for IBD bispecific - European Biotechnology Magazine
Boehringer Ingelheim is continuing its international shopping tour for innovative drug candidates – and once again ends up in China. The German pharmaceutical group has entered into a licensing and development partnership with Shanghai-based Simcere Pharmaceutical Group to advance a novel bispecific antibody for the treatment of inflammatory bowel disease (IBD). The post China again: Boehringer turns to Shanghai for IBD bispecific appeared first…
Coverage Details
Bias Distribution
- 58% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
